Table 4 Correlation of SIRT3 expression in RCC with clinicopathological parameters
From: Evaluation of ARK5 and SIRT3 expression in renal cell carcinoma and their clinical significance
|  | Negative (n = 14)(%) | Positive (n = 44)(%) | Test | P value |
|---|---|---|---|---|
Gender | Â | Â | Fisher Exact Test | 0.53 |
 Male | 10 (71.4%) | 26 (59.1%) | ||
 Female | 4 (28.6%) | 18 (40.9%) | ||
Histological type | Â | Â | Chi square | 0.21 |
 Clear | 9 (64.3%) | 23 (52.2%) | ||
 Papillary | 3 (21.4%) | 4 (9.1%) | ||
 Chromophobe | 1 (7.1%) | 15 (34.1%) | ||
 Others | 1 (7.1%) | 2 (4.5%) | ||
Grade | ||||
 1 | 4 (28.6%) | 11 (25%) | Chi-square | 0.17 |
 2 | 8 (57.1%) | 13 (29.5%) | ||
 3 | 1 (7.1%) | 13 (29.5%) | ||
 4 | 1 (7.1%) | 7 (15.9%) | ||
Apoptosis | 2.93 ± 0.83 | 2.32 ± 0.86 | Mann–Whitney | 0.022* |
Mitosis | 2.1 ± 1.1 | 2.97 ± 1.1 | Mann–Whitney | 0.02* |
Tumour extent | ||||
 T1 | 9 (64.3%) | 11 (25%) | Chi-square | 0.042* |
 T2 | 4 (28.6%) | 17 (38.6%) | ||
 T3 | 1 (7.1%) | 14 (31.8%) | ||
 T4 | 0 (00%) | 2 (4.5%) | ||
LN | ||||
 negative | 14 (100%) | 42 (95.4%) |  | 0.57 |
 Positive | 0 (00%) | 2 (4.5%) | ||
Stage | Â | Â | Chi-square | 0.039* |
 I | 9(64.3%) | 11(25%) |  |  |
 II | 4 (28.6%) | 16 (36.4%) | ||
 III | 1 (7.1%) | 15 (34.1%) | ||
 IV | 0 (00%) | 2 (4.5%) | ||
Response to chemotherapy | ||||
 No | 1 (7.1%) | 12 (27.2%) | Chi square | 0.027* |
 Partial | 7 (50%) | 18 (40.9%) | ||
 Complete | 4 (28.6%) | 2 (4.5%) | ||